Hybrigenics releases inecalcitol preclinical trial results
In the trial, inecalcitol was 11 times potent than a naturally active metabolite of vitamin D, calcitriol in suppressing the growth in-vitro of the human hormone-dependent prostate cancer
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Under the agreement, MANF-based therapeutic will be developed using Generex’s RapidMist technology in conjunction with oral-insulin spray technology Oral-lyn. Amarantus chief scientific officer John Commissiong said MANF’s profile